Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients.

abstract：:We aimed to construct and assess the psychometric properties of the My Medicines and Me Questionnaire (M3Q), a self-report side-effect questionnaire for mental health patients. Thirty individuals taking a psychotropic medication completed the M3Q side-effect checklist along with the Liverpool University Neuroleptic Si...

journal_title：International clinical psychopharmacology

authors： Ashoorian DM,Davidson RM,Rock DJ,Dragovic M,Clifford RM

更新日期：2015-07-01 00:00:00

abstract：:The selective serotonin reuptake inhibitors (SSRIs) have well-established antidepressant activity and have also demonstrated efficacy in a number of anxiety disorders, including panic disorder. The SSRIs, escitalopram and sertraline, are well-tolerated and movement disorders are rarely associated with their use. We pr...

journal_title：International clinical psychopharmacology

authors： Altindag A,Yanik M,Asoglu M

更新日期：2005-05-01 00:00:00

abstract：:Quetiapine ('Seroquel') is a well-tolerated, novel, atypical antipsychotic with consistent efficacy in the treatment of schizophrenia. To date, no clinical studies have evaluated the effect of quetiapine in patients who only partially respond to conventional antipsychotics, yet this type of patient is most frequently ...

journal_title：International clinical psychopharmacology

authors： Emsley RA,Raniwalla J,Bailey PJ,Jones AM

更新日期：2000-05-01 00:00:00

abstract：:Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, randomized, double-bl...

journal_title：International clinical psychopharmacology

authors： Khan A,Sambunaris A,Edwards J,Ruth A,Robinson DS

更新日期：2014-03-01 00:00:00

abstract：:Neuroleptics are of established efficacy in mania. Controlled data on the use of olanzapine in mania is however, absent. In this study, 30 patients meeting DSM-IV criteria for mania were randomly allocated to receive either olanzapine or lithium in a 4 week double-blind randomized controlled design. There were no sign...

journal_title：International clinical psychopharmacology

authors： Berk M,Ichim L,Brook S

更新日期：1999-11-01 00:00:00

abstract：:The treatment of depressed patients with a fixed dose of amitriptyline is compared to treatment with an individualized dose calculated by means of a simple pharmacokinetic test. Clinical response and the development of side-effects are compared between the two groups of patients. Although the numbers in the groups wer...

journal_title：International clinical psychopharmacology

authors： Roy D,Dawling S

更新日期：1987-10-01 00:00:00

abstract：:The clock-drawing test (CDT) is used widely to evaluate cognitive disorders, but its role in the assessment of psychotic disorders has not been studied. We sought to examine whether the CDT plays a role as an indicator of psychosis and to establish its sensitivity to clinical improvement of psychosis. The CDT was admi...

journal_title：International clinical psychopharmacology

authors： Tene O,Sigler M,Shiloh R,Weizman A,Aizenberg D

更新日期：2016-05-01 00:00:00

abstract：:Depressive symptoms are associated with poor outcomes, increased risk of relapse, and high suicide rates in patients with schizophrenia and schizoaffective disorder. This randomized, open-label, parallel-group, flexible-dose study (NCT00640562) assessed the efficacy of quetiapine extended release (XR) versus risperido...

journal_title：International clinical psychopharmacology

authors： Di Fiorino M,Montagnani G,Trespi G,Kasper S

更新日期：2014-05-01 00:00:00

abstract：:For more than 30 years, lithium has been the drug of choice for the treatment of bipolar disorder. However, it has numerous adverse effects, a relatively slow onset of action, many common drug-drug interactions, and a narrow therapeutic index. Because of these problems, researchers looked for alternative and/or adjunc...

journal_title：International clinical psychopharmacology

authors： Lennkh C,Simhandl C

更新日期：2000-01-01 00:00:00

abstract：:Duloxetine, an inhibitor of serotonin and norepinephrine reuptake, has been approved for the treatment of major depressive disorder. In this analysis, data from eight, double-blind, placebo-controlled duloxetine trials were pooled, and the response to duloxetine treatment (40-120 mg/day) was compared between patients ...

journal_title：International clinical psychopharmacology

authors： Perahia DG,Kajdasz DK,Royer MG,Walker DJ,Raskin J

更新日期：2006-09-01 00:00:00

abstract：:Recent studies have shown that the use of subscales derived from the Hamilton Depression (HAM-D) rating scale are just as reliable and enhance sensitivity for detecting response and remission after antidepressant treatment. The purpose of the present study was to determine if the responses on two items of the HAM-D sc...

journal_title：International clinical psychopharmacology

authors： Silverstone PH,Entsuah R,Hackett D

更新日期：2002-11-01 00:00:00

abstract：:The prevalence of somnambulistic-like behaviour related to treatment with lithium alone or in combination with other psychotropic medications was evaluated in patients attending a lithium clinic. A written questionnaire on somnambulistic-like behaviour was completed by 389 patients. Information was provided on the tim...

journal_title：International clinical psychopharmacology

authors： Landry P,Warnes H,Nielsen T,Montplaisir J

更新日期：1999-05-01 00:00:00

abstract：:This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria. In a 50-week, open-label trial, stable patients received long-acting injectable risperidone every 2 weeks. Remission criteria included severity (absent-mild ratings on core symptoms ...

journal_title：International clinical psychopharmacology

authors： Docherty JP,Bossie CA,Lachaux B,Bouhours P,Zhu Y,Lasser R,Gharabawi GM

更新日期：2007-01-01 00:00:00

abstract：:A variety of cognitive impairments can be observed in patients with schizophrenia, including substantial reductions in the intelligence quotient (IQ). I propose that these impairments can be best understood in terms of the abnormal processes underlying the signs and symptoms manifested by the patient at the time of th...

journal_title：International clinical psychopharmacology

authors： Frith CD

更新日期：1995-09-01 00:00:00

abstract：:Several cardiovascular risk factors have been linked to antipsychotic treatment and cardiovascular mortality is increased in these patients compared to the general population. The full metabolic syndrome (or its components) is associated with an increased risk of cardiovascular disorders. The prevalence of the metabol...

journal_title：International clinical psychopharmacology

authors： Hägg S,Lindblom Y,Mjörndal T,Adolfsson R

更新日期：2006-03-01 00:00:00

abstract：:Clozapine is the only evidence-based antipsychotic for treatment-resistant schizophrenia. However, it has considerable side effects, limiting its usability and reducing patients' adherence. One of the most common and distressing side effects is hypersalivation, which can be debilitating, stigmatizing and potentially d...

journal_title：International clinical psychopharmacology

authors： Segev A,Evans A,Hodsoll J,Whiskey E,Sheriff RS,Shergill S,MacCabe JH

更新日期：2019-03-01 00:00:00

abstract：:In a total population of patients with a schizophrenic syndrome, the amount of antipsychotic drugs during a defined period was studied. Doses of antipsychotics were higher in males than in females, low to moderate in most patients, and decreased with the duration of illness. There was a significant negative correlatio...

journal_title：International clinical psychopharmacology

authors： Lindström E,Widerlöv B,von Knorring L

更新日期：1996-12-01 00:00:00

abstract：:The present study aimed to systematically compare overall loss to follow-up, discontinuation rates because of adverse events and discontinuation rates because of a lack of efficacy in published studies assessing the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs) compared to other second-g...

journal_title：International clinical psychopharmacology

authors： Gartlehner G,Hansen RA,Carey TS,Lohr KN,Gaynes BN,Randolph LC

更新日期：2005-03-01 00:00:00

abstract：:We report that perospirone may have had positive effects on the obesity of three patients with schizophrenia and on the fasting blood sugar (FBS) and HbA1C of two of them who had type 2 diabetes mellitus. ...

journal_title：International clinical psychopharmacology

authors： Nishida M,Nakamura M

更新日期：2004-01-01 00:00:00

abstract：:The aim was to evaluate the efficacy of venlafaxine extended release (ER) on characteristics of resilience, measured by the Connor-Davidson Resilience Scale, in patients with posttraumatic stress disorder (PTSD). Data were evaluated from a randomized, 6-month, international, multicenter study of adult outpatients with...

journal_title：International clinical psychopharmacology

authors： Davidson J,Baldwin DS,Stein DJ,Pedersen R,Ahmed S,Musgnung J,Benattia I,Rothbaum BO

更新日期：2008-09-01 00:00:00

abstract：:The 6-month prevalence of depression in the Italian community was evaluated by means of the modified-Mini-International-Neuropsychiatric Interview (MINI) administered with a computer-prompted interview to a representative panel of 3550 individuals. Major depression and minor depression accounted for 8.0% and 2.9% of t...

journal_title：International clinical psychopharmacology

authors： Dubini A,Mannheimer R,Pancheri P

更新日期：2001-01-01 00:00:00

abstract：:This study is aimed at investigating the efficacy and tolerability of mirtazapine in a generalized social anxiety disorder. Sixty patients with generalized social anxiety disorder were randomly allocated to receive mirtazapine (30-45 mg/day) (n= 30) or placebo (n= 30) for 12 weeks in a double-blind study design. Prima...

journal_title：International clinical psychopharmacology

authors： Schutters SI,Van Megen HJ,Van Veen JF,Denys DA,Westenberg HG

更新日期：2010-09-01 00:00:00

abstract：:Post-traumatic stress disorder (PTSD) is frequently treated with antidepressant medications, especially the newer selective serotonergic antidepressants which have documented efficacy in PTSD. Analogous to depression, however, some PTSD patients may not have a satisfactory response to these agents. This case report de...

journal_title：International clinical psychopharmacology

authors： Hamner MB,Frueh BC

更新日期：1998-09-01 00:00:00

abstract：:Twelve normal weight healthy male volunteers participated in a double-blind, placebo-controlled trial of the effects of d- and l-fenfluramine, d-amphetamine, and the interactions between the two isomers of fenfluramine with amphetamine, on cortisol secretion. d-Fenfluramine and d-amphetamine in combination produced th...

journal_title：International clinical psychopharmacology

authors： Feeney S,Goodall E,Silverstone T

更新日期：1993-10-01 00:00:00

abstract：:Scientific, professional, and governmental bodies have in recent years intensified efforts to formulate guidelines for the treatment of depression with the goal that medical practice should comply with these standards and thus improve patient care. 'Evidence-based medicine' demands that medical practice should explici...

journal_title：International clinical psychopharmacology

authors： Linden M

更新日期：1999-06-01 00:00:00

abstract：:Severe orthostatic and cardiorespiratory dysregulation may occur during institution of clozapine therapy both during concomitant benzodiazepine medication and on reinstitution of clozapine after a washout period. Extensive medical and neurological workup before and after the trials can nevertheless be normal. The abse...

journal_title：International clinical psychopharmacology

authors： Bredbacka PE,Paukkala E,Kinnunen E,Koponen H

更新日期：1993-10-01 00:00:00

abstract：:Treatment of psychotic symptoms with traditional neuroleptics has been complicated by acute extrapyramidal syndromes (EPS) and late occurring tardive dyskinesia. These widely prevalent disorders have both motor and mental components which impose additional impairments on patients who are already substantially limited ...

journal_title：International clinical psychopharmacology

authors： Casey DE

更新日期：1997-02-01 00:00:00

abstract：:The tendency of antipsychotics to produce extrapyramidal side-effects varies inversely with their antimuscarinic activity. This paper reviews the antipsychotic and antimuscarinic potency of these drugs and compares the total antimuscarinic activity in standard daily doses of antipsychotics, antiparkinson agents and an...

journal_title：International clinical psychopharmacology

authors： Menkes DB,Clarkson HO,Caradoc-Davies G,Mullen PE

更新日期：1987-01-01 00:00:00

abstract：:Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor that is Food and Drug Administration approved for once-daily treatment of major depressive disorder in adults. Secondary and post-hoc analyses were carried out on data from a positive 10-week, randomized, dou...

journal_title：International clinical psychopharmacology

authors： Montgomery SA,Mansuy L,Ruth AC,Li D,Gommoll C

更新日期：2014-01-01 00:00:00

abstract：:This study evaluated the efficacy of pregabalin augmentation of antidepressant treatment in patients with posttraumatic stress disorder (PTSD). Nine patients meeting Diagnostic and Statistical Manual, fourth edition criteria for PTSD who were on stable doses of antidepressants were treated open label with flexibly dos...

journal_title：International clinical psychopharmacology

authors： Pae CU,Marks DM,Han C,Masand PS,Patkar AA

更新日期：2009-01-01 00:00:00